Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zidovudine + lamivudine or tenofovir + emtricitabine
- Development stage
- Unknown
- Lead developer
- International Antiviral Therapy Evaluation Center
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This refers to the antiretroviral therapy (ART) regimens evaluated in a Phase 4 clinical trial conducted by the International Antiviral Therapy Evaluation Center (IATEC). The study compared the older thymidine analogue-based combination of zidovudine and lamivudine (AZT/3TC) with the newer combination of tenofovir disoproxil fumarate and emtricitabine (TDF/FTC). Both regimens consist of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that inhibit the HIV-1 reverse transcriptase enzyme, preventing viral replication. The primary focus of the trial was to determine if switching from AZT/3TC to TDF/FTC could prevent the progression of or reverse peripheral lipoatrophy, a condition characterized by fat loss that is frequently associated with older thymidine analogue NRTIs like zidovudine.
- Brand names
- CombivirTruvada
- Other names
- AZT/3TCTDF/FTCzidovudine/lamivudinetenofovir disoproxil fumarate/emtricitabine
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on zidovudine + lamivudine or tenofovir + emtricitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zidovudine + lamivudine or tenofovir + emtricitabine.